Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 41

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 41
---
 or results of operations following the Merger. Any decline or potential
decline in the combined company’s financial condition or results of operations may cause significant variations in the market price
of the combined company’s securities.

DiamiR has never generated revenue from product sales and all of DiamiR’s product candidates are currently in the pre-commercial stage, and DiamiR may continue to incur significant losses for the foreseeable future and never generate revenue from product sales.

DiamiR is a molecular diagnostic company focused on developing minimally
invasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer’s, Parkinson’s, other neurodegenerative
diseases, and cancer. The proprietary technology they developed is based on quantitative analysis of circulating organ-enriched microRNAs
in plasma. Short-term objectives of the Company include the development of Lab-Developed tests (LDTs) under CLIA guidelines based on the
identified miRNA expression signatures. The tests will be used for screening, patient stratification, as well as disease and treatment
monitoring. DiamiR has devoted most of its financial resources to conducting studies on analysis of circulating organ-enriched miRNA biomarkers
and building its patent portfolio. DiamiR has not completed development of any product candidate and has therefore not generated any revenues
from product sales. DiamiR’s ability to fully develop its products and market them successfully is depending on may factors, some
of which are out of their control and many of which are described elsewhere in this prospectus. Although DiamiR has received revenue in the past from providing testing services to life sciences companies, and may again in the future, they cannot be certain that such services will bring sufficient revenue to support its operation and R&D. Thus, DiamiR may not be able to generate a profit until its product candidates become profitable, which may never occur.

The Combined Company will need to raise additional capital by issuing securities or debt or through licensing or other strategic arrangements, which may cause dilution to the Combined Company’s stockholders or restrict the Combined Company’s operations or impact its proprietary rights.

The Combined Company may
be required to raise additional funds sooner than currently planned. If either or both of Aptorum or DiamiR hold less cash at the time
of the Merger Closing than the parties currently expect, the Combined Company will need to raise additional capital sooner than expected.
Additional financing may not be available to the Combined Company when it needs it or may not be available on favorable terms